Adamis Pharmaceuticals Corp expected to post a loss of 4  cents a share - Earnings Preview

DMK Pharmaceuticals

09/08/2022 03:03

* Adamis Pharmaceuticals Corp  ADMP.OQ   ADMP.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 15. 
    * The San Diego California-based  company is expected to
report  a
74.6% decrease in revenue to $1.018 million from $4.01 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Adamis
Pharmaceuticals
Corp is for a loss of 4 cents per share. For the same quarter
last year, the company reported a loss of 6 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adamis
Pharmaceuticals Corp is $0.42​, above​ its last closing price
of $0.37. ​​​

This summary was machine generated August 9 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated